SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 9, 2004
CUBIST PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 0-21379 | | 22-3192085 |
(State or Other Jurisdiction | | (Commission | | (IRS Employer |
of Incorporation) | | File Number) | | Identification No.) |
| | | | |
65 Hayden Avenue, Lexington, Massachusetts 02421 |
(Address of Principal Executive Offices) (Zip Code) |
| | | | |
Registrant’s telephone number, including area code: (781) 860-8660 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry Into a Material Definitive Agreement.
On December 9, 2004, the Compensation Committee of the Board of Directors of Cubist Pharmaceuticals, Inc. approved a Short Term Incentive Plan (“STIP”) to reward Cubist’s managers and certain key individual employee contributors with annual cash awards based on each eligible employee’s seniority in the company, Cubist’s achievement of its company goals and the individual employee’s achievement of personal goals for the relevant calendar year.
The terms and conditions of the STIP are attached hereto as Exhibit 10.1.
Item 9.01 Financial Statements and Exhibits.
10.1 | | STIP Terms and Conditions |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CUBIST PHARMACEUTICALS, INC. |
| |
| |
| By: | /s/ Christopher D.T. Guiffre | |
| | Christopher D.T. Guiffre |
| | Senior Vice President and |
| | Chief Financial Officer |
| | |
Dated: December 13, 2004 | | |
2
